EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Asperosaponin VI Alleviates Cisplatin‐Induced Liver Injury Through the Nrf2/HO‐1 Signaling Pathway

Han-Hua Li, Xiao-Ming Zhou, Chuan-Wei Sun, Zhi-Feng Huang, Zu-An Liu, Hongming Lou iD, Huining Bian, Shao-Yi Zheng, Wen Lai, XueQing Yao

Immunity, Inflammation and Disease · 2026-04 · 14 (4)

DOI: 10.1002/iid3.70454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 27.04.2026. Verfasst von Han-Hua Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences,…. Hauptthemen laut MEDLINE: Saponins, NF-E2-Related Factor 2, Cisplatin, Chemical and Drug Induced Liver Injury. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leading Innovation Specialist Support Program of Guangdong Province, the Science and Technology Planning Project of Ganzhou, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cisplatin (Cis) chemotherapy‐induced hepatotoxicity frequently leads to treatment interruption or dose reduction, ultimately compromising therapeutic outcomes. Asperosaponin VI (AVI), a bioactive triterpenoid saponin extracted from Dipsacus asperoides , has demonstrated anti‐inflammatory and antioxidant properties in various pathological conditions. However, its hepatoprotective efficacy against cisplatin‐induced hepatotoxicity and underlying molecular mechanisms remain poorly understood.

Methods

This study utilized both in vitro (LO2 human hepatocytes) and in vivo (C57BL/6mice n = 4 per group) experimental approaches to investigate the protective effects of AVI against cisplatin‐induced acute hepatotoxicity. Cell viability was assessed using CCK‐8 assay, while hepatic injury was evaluated through histopathological examination, biochemical markers (ALT, AST, GSH), and TUNEL staining. The involvement of the nuclear factor erythroid 2‐related factor 2/heme oxygenase‐1 (Nrf2/HO‐1) signaling pathway was confirmed using Brusatol, a specific Nrf2 inhibitor.

Results

AVI (400 μM in vitro; 20 mg/kg in vivo) significantly attenuated cisplatin‐induced cytotoxicity in LO2cells and reduced hepatic injury in mice. Treatment with AVI markedly decreased serum transaminase levels (ALT: 68.3 ± 30.4 vs. 358.1 ± 67.5 U/L, p < 0.001; AST: 129.0 ± 45.9 vs. 374.4 ± 49.5 U/L, p < 0.001), ameliorated oxidative stress, and suppressed inflammatory responses. AVI significantly upregulated Nrf2and HO‐1 protein expressions while downregulating pro‐inflammatory mediators (TNF‐α, IL‐1β, IL‐6) and apoptotic markers (Caspase‐1, Caspase‐3, NLRP3). Pharmacological inhibition of Nrf2 with Brusatol abolished the protective effects of AVI.

Conclusions

AVI effectively protects against cisplatin‐induced hepatotoxicity through activation of the Nrf2/HO‐1 signaling pathway, suggesting its potential as a novel hepatoprotective agent in cisplatin‐based chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SaponinsNF-E2-Related Factor 2CisplatinChemical and Drug Induced Liver InjuryHeme Oxygenase-1AnimalsSignal TransductionMiceHumansMice, Inbred C57BLMaleHepatocytesOxidative StressCell LineApoptosis

Stichwörter der Autor:innen

HO‐1Nrf2apoptosisasperosaponin VIcisplatinherbal medicineinflammatory reactionoxidative stress

Substanzen

SaponinsNF-E2-Related Factor 2CisplatinHeme Oxygenase-1Nfe2l2 protein, mouse

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Burns and Wound Repair Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
  • Department of Neurology, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Hongming Lou

Förderung

  • Leading Innovation Specialist Support Program of Guangdong Province, the Science and Technology Planning Project of Ganzhou
  • National Natural Science Foundation of China

Zitieren

APA

Li, H. H., Zhou, X. M., Sun, C. W., Huang, Z. F., Liu, Z. A., Lou, H., Bian, H., Zheng, S. Y., Lai, W., & Yao, X. (2026). Asperosaponin VI Alleviates Cisplatin‐Induced Liver Injury Through the Nrf2/HO‐1 Signaling Pathway. Immunity, Inflammation and Disease, 14(4). https://doi.org/10.1002/iid3.70454

Vancouver

Li HH, Zhou XM, Sun CW, Huang ZF, Liu ZA, Lou H, et al. Asperosaponin VI Alleviates Cisplatin‐Induced Liver Injury Through the Nrf2/HO‐1 Signaling Pathway. Immunity, Inflammation and Disease. 2026;14(4). doi:10.1002/iid3.70454

BibTeX
@article{Li2026,
  author = {Li, Han-Hua and Zhou, Xiao-Ming and Sun, Chuan-Wei and Huang, Zhi-Feng and Liu, Zu-An and Lou, Hongming and Bian, Huining and Zheng, Shao-Yi and Lai, Wen and Yao, XueQing},
  title = {Asperosaponin VI Alleviates Cisplatin‐Induced Liver Injury Through the Nrf2/HO‐1 Signaling Pathway},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/iid3.70454}
}
Kostenlos starten →